Policy question 1: Should country X recommend Mpox vaccines for populations in the community of high risk of being exposed to Mpox during the current outbreak?
| Population | Populations in the community at high risk of Mpox in outbreak settings |
| Intervention | Administration of the licensed or WHO prequalified Mpox vaccine (MVA-BN [ 2doses]. LC-16 [1 dose] or A-CAM2000 [1 dose]) |
| Comparison | none |
| Outcome | Reduction in incidence of Mpox infection, (hospitalization and death) |
Policy question 2 : Should country X recommend Mpox vaccines for healthcare workers and frontline workers at high risk of being exposed during the current outbreak?
| Population | Healthcare workers and frontline workers at high risk of exposure to Mpox |
| Intervention | Administration of the licensed or WHO prequalified Mpox vaccine (MVA-BN [ 2doses]. LC-16 [1 dose] or A-CAM2000 [1 dose]) |
| Comparison | none |
| Outcome | Reduction in incidence of Mpox infection, (hospitalization and death) |
